OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentEstablished

Buserelin

Buserelin is one of the original GnRH agonists, approved in Europe and Canada in the 1980s for advanced prostate cancer and also used in endometriosis and fertility treatment; it is not sold in the United States.